Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the signifi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2019/5679518 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225911590289408 |
|---|---|
| author | Jiwon M. Lee Jae Won Yang Andreas Kronbichler Michael Eisenhut Gaeun Kim Keum Hwa Lee Jae Il Shin |
| author_facet | Jiwon M. Lee Jae Won Yang Andreas Kronbichler Michael Eisenhut Gaeun Kim Keum Hwa Lee Jae Il Shin |
| author_sort | Jiwon M. Lee |
| collection | DOAJ |
| description | Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission. |
| format | Article |
| id | doaj-art-5b56bb3918b14ca4ae478f18875b6fd5 |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-5b56bb3918b14ca4ae478f18875b6fd52025-08-20T02:05:13ZengWileyJournal of Immunology Research2314-88612314-71562019-01-01201910.1155/2019/56795185679518Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-AnalysisJiwon M. Lee0Jae Won Yang1Andreas Kronbichler2Michael Eisenhut3Gaeun Kim4Keum Hwa Lee5Jae Il Shin6Department of Pediatrics, Chungnam National University College of Medicine, Daejeon, Republic of KoreaDepartment of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Gangwon, Republic of KoreaDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, AustriaPediatric Department, Luton & Dunstable University Hospital NHS Foundation Trust, Luton, UKKeimyung University College of Nursing, Daegu, Republic of KoreaDepartment of Pediatric Nephrology, Severance Children’s Hospital, Seoul, Republic of KoreaDepartment of Pediatric Nephrology, Severance Children’s Hospital, Seoul, Republic of KoreaIntroduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.http://dx.doi.org/10.1155/2019/5679518 |
| spellingShingle | Jiwon M. Lee Jae Won Yang Andreas Kronbichler Michael Eisenhut Gaeun Kim Keum Hwa Lee Jae Il Shin Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis Journal of Immunology Research |
| title | Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis |
| title_full | Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis |
| title_fullStr | Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis |
| title_full_unstemmed | Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis |
| title_short | Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis |
| title_sort | increased serum soluble urokinase type plasminogen activator receptor supar levels in fsgs a meta analysis |
| url | http://dx.doi.org/10.1155/2019/5679518 |
| work_keys_str_mv | AT jiwonmlee increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis AT jaewonyang increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis AT andreaskronbichler increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis AT michaeleisenhut increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis AT gaeunkim increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis AT keumhwalee increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis AT jaeilshin increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis |